Mesenchymal chondrosarcoma

Summary

Mesenchymal chondrosarcoma (MONDO:0006853) is a disease and 5 clinical trials. Molecularly, HEY1::NCOA2 Fusion confers sensitivity to Trabectedin in Mesenchymal Chondrosarcoma (CIViC Level C); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include pazopanib, ifosfamide, and regorafenib. A subtype of small cell sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mesenchymal chondrosarcoma
Mondo ID	MONDO:0006853
EFO	EFO:1001041
MeSH	D018211
DOID	DOID:4545
NCIT	C3737
UMLS	C0206637
MedGen	104904
GARD	0024490
MedDRA	10027389
Is cancer (heuristic)	no

Also known as: mesenchymal chondrosarcoma

Disease family

This is a subtype of small cell sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › small cell sarcoma › mesenchymal chondrosarcoma

Related subtypes (5): small cell osteogenic sarcoma, desmoplastic small round cell tumor, EWSR1-negative small round cell tumor, sarcoma with BCOR genetic alterations, round cell sarcoma with EWSR1-non-ETS fusion

Subtypes (2): pediatric mesenchymal chondrosarcoma, adult mesenchymal chondrosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Trabectedin, Vismodegib.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02180867	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT01267955	PHASE2	ACTIVE_NOT_RECRUITING	Vismodegib in Treating Patients With Advanced Chondrosarcomas
NCT04305548	PHASE2	RECRUITING	Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
NCT02048371	PHASE2	COMPLETED	SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
NCT02821507	PHASE2	COMPLETED	Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAZOPANIB	4	3
IFOSFAMIDE	4	1
REGORAFENIB	4	1
TRABECTEDIN	4	1
VISMODEGIB	4	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items; also 6 diagnostic.

Molecular subtype	Therapy	Effect	Level	CIViC
HEY1::NCOA2 Fusion	Trabectedin	Sensitivity/Response	CIViC C	EID12585
HEY1::NCOA2 Fusion	Imatinib	Sensitivity/Response	CIViC D	EID10798